Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism

Pharmacogenetics and Genomics

Volumn 18, Issue 1, 2008, Pages 11-24

  Hart, Steven N ^a   Wang, Shuang ^b   Nakamoto, Kaori ^a   Wesselman, Christopher ^a   Li, Ye ^a   Zhong, Xiao Bo ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Mailman School of Public Health   (United States)

Author keywords

Cytochrome P450 oxidoreductase; Drug metabolism; Microsomal P450 enzymes; Single nucleotide polymorphisms

Indexed keywords

AMINO ACID; CYTOCHROME C; CYTOCHROME P450 REDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CATALYSIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INFANT; INTRON; LIVER; LIVER MICROSOME; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CATALYSIS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROSOMES, LIVER; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 38549085263     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f2f121     Document Type: Article

References (52)

1. Guengerich FP. Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 2004; 36:159-197.
2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
3. Rettie AE, Tai G. The pharmacogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006; 6:223-227.
4. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007; 7:99-111.
5. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6:369-383.
6. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, et al. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 2006; 79:325-338.
7. Porter TD, Coon MJ. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 1991; 266: 13469-13472.
8. Shen AL, O'Leary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal nadph-cytochrome p450 oxidoreductase. J Biol Chem 2002; 277:6536-6541.
9. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, et al. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003; 23:6103-6116.
10. Gu J, Weng Y, Zhang QY, Cui H, Behr M, Wu L, et al. Liver-specific deletion of the NADPH-cytochrome p450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome p450 and heme oxygenase. J Biol Chem 2003; 278: 25895-25901.
11. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, et al. Inactivation of the hepatic cytochrome p450 system by conditional deletion of hepatic cytochrome p450 reductase. J Biol Chem 2003; 278:13480-13486.
12. Shephard EA, Phillips IR, Santisteban I, West LF, Palmer CN, Ashworth A, et al. Isolation of a human cytochrome P-450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2. Ann Hum Genet 1989; 53(Pt 4):291-301.
13. Zhao Z, Fu YX, Hewett-Emmett D, Boerwinkle E. Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. Gene 2003; 312:207-213.
14. All SNPs in the NCBI dbSNP database at (http://www.ncbi.nlm.nih.gov/SNP/ snp_ref.cgi?locusId=5447&chooseRs=all).
15. Flück CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant p450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228-230.
16. Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, et al. Congenital adrenal hyperplasia caused by mutant p450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004; 363:2128-2135.
17. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729-749.
18. Fukami M, Horikawa R, Nagai T, Tanaka T, Naiki Y, Sato N, et al. Cytochrome p450 oxidoreductase gene mutations and Antley-Bixler syndrome with abnormal genitalia and/or impaired steroidogenesis: molecular and clinical studies in 10 patients. J Clin Endocrinol Metab 2005; 90:414-426.
19. Flück CE, Miller WL. P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia. Curr Opin Pediatr 2006; 18:435-441.
20. Krone N, Dhir V, Ivison HE, Arlt W. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf) 2007; 66: 162-172.
21. Adachi M, Tachibana K, Asakura Y, Suwa S, Nishimura G. A male patient presenting with major clinical symptoms of glucocorticoid deficiency and skeletal dysplasia, showing a steroid pattern compatible with 17alphahy-droxylase/17,20-lyase deficiency, but without obvious CYP17 gene mutations. Endocr J 1999; 46:285-292.
22. Reardon W, Smith A, Honour JW, Hindmarsh P, Das D, Rumsby G, et al. Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 2000; 37:26-32.
23. Han JF, Wang SL, He XY, Liu CY, Hong JY. Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity. Toxicol Sci 2006; 91:42-48.
24. Wang SL, Han JF, He XY, Wang XR, Hong JY. Genetic variation of human cytochrome p450 reductase as a potential biomarker for mitomycin c-induced cytotoxicity. Drug Metab Dispos 2007; 35:176-179.
25. Hart S, Li Y, Nakamoto K, Wesselman C, Zhong XB. Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab Pharmacokinet 2007; 22:322-326.
26. Lu AY, Levin W. Partial purification of cytochrome P-450 and P-448 from rat liver microsomes. Biochem Biophys Res Commun 1972; 46:1334-1339.
27. Philips AH, Langdon RG. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. J Biol Chem 1962; 237:2652-2660.
28. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, et al. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 1996; 331:145-169.
29. Ko JW, Desta Z, Flockhart DA. Human n-demethylation of (s)-mephenytoin by cytochrome p450s 2C9 and 2B6. Drug Metab Dispos 1998; 26: 775-778.
30. Robertson P, DeCory HH, Madan A, Parkinson A. In vitro inhibition and induction of human hepatic cytochrome p450 enzymes by modafinil. Drug Metab Dispos 2000; 28:664-671.
31. Hartley DP, Klaassen CD. Detection of chemical-induced differential expression of rat hepatic cytochrome P450 mRNA transcripts using branched DNA signal amplification technology. Drug Metab Dispos 2000; 28:608-616.
32. Czerwinski M, Opdam P, Madan A, Carroll K, Mudra DR, Gan LL, et al. Analysis of CYP mRNA expression by branched DNA technology. Methods Enzymol 2002; 357:170-179.
33. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignments through sequence weighting, position specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22:4673-4680.
34. Lambert C, Léonard N, De Bolle X, Depiereux E. ESyPred3D: prediction of proteins 3D structures. Bioinformatics 2002; 18:1250-1256.
35. Needleman SB, Wunsch CD. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J Mol Biol 1970; 48:443-453.
36. Warren L. DeLano 'The PyMOL Molecular Graphics System'. DeLano Scientific LLC, San Carlos, California, USA. http://www.pymol.org
37. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 1999; 292:195-202.
38. Jones DT, Taylor WR, Thornton JM. A model recognition approach to the prediction of all-helical membrane protein structure and topology. Biochemistry 1994; 33:3038-3049.
39. Horecker BL. Triphosphopyridine nucleotide cytochrome c reductase in liver. J Biol Chem 1950; 183:593-605.
40. Williams CH, Kamin H. Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J Biol Chem 1962; 237:587-595.
41. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997; 94:8411-8416.
42. Lin D, Black SM, Nagahama Y, Miller WL. Steroid 17 alpha-hydroxylase and 17,20-lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 1993; 132:2498-2506.
43. Yanagibashi K, Hall PF. Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J Biol Chem 1986; 261:8429-8433.
44. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57:119-137.
45. Daly AK. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 2004; 4:1733-1744.
46. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005; 5:6-13.
47. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2007; 45: 188-190.
48. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee at: http://www.cypalleles.ki.se/.
49. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 2004; 19: 83-95.
50. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 2006; 281: 35975-35982.
51. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science 2002; 297:1143.
52. Lo HS, Wang Z, Hu Y, Yang HH, Gere S, Buetow KH, et al. Allelic variation in gene expression is common in the human genome. Genome Res 2003; 13:1855-1862.